Urvashi Tyagi - Resmed Chief Officer
| RMEA Stock | EUR 21.60 0.20 0.92% |
Insider
Urvashi Tyagi is Chief Officer of Resmed Inc DRC
| Phone | 858 836 5000 |
| Web | https://www.resmed.com |
Resmed Management Efficiency
The company has return on total asset (ROA) of 0.1155 % which means that it generated a profit of $0.1155 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2352 %, meaning that it generated $0.2352 on every $100 dollars invested by stockholders. Resmed's management efficiency ratios could be used to measure how well Resmed manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Manfred Werner | Sartorius Aktiengesellschaft | N/A | |
| BE MBA | ResMed Inc | 50 | |
| Constance Bienfait | ResMed Inc | N/A | |
| Pascale Boissel | Sartorius Stedim Biotech | N/A | |
| AM AM | ResMed Inc | 80 | |
| David Rosa | Intuitive Surgical | 55 | |
| John Mackay | Sartorius Aktiengesellschaft | 61 | |
| Gary Loeb | Intuitive Surgical | N/A | |
| Manohar Kuppusami | Sartorius Aktiengesellschaft | N/A | |
| Philip Kim | Intuitive Surgical | N/A | |
| Rene Faber | Sartorius Aktiengesellschaft | 48 | |
| Mei Wang | Sartorius Aktiengesellschaft | N/A | |
| Gary Guthart | Intuitive Surgical | 57 | |
| Olivier Guitard | Sartorius Stedim Biotech | N/A | |
| Marshall Mohr | Intuitive Surgical | 67 | |
| Julian Nikolchev | Intuitive Surgical | 69 | |
| Giorgio Iannella | EssilorLuxottica Socit anonyme | N/A | |
| Amy Wakeham | ResMed Inc | N/A | |
| Francesco Milleri | EssilorLuxottica Socit anonyme | 64 | |
| David Pendarvis | ResMed Inc | 64 | |
| Rene Faber | Sartorius Stedim Biotech | 43 | |
Management Performance
| Return On Equity | 0.24 | |||
| Return On Asset | 0.12 |
Resmed Inc DRC Leadership Team
Elected by the shareholders, the Resmed's board of directors comprises two types of representatives: Resmed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Resmed. The board's role is to monitor Resmed's management team and ensure that shareholders' interests are well served. Resmed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Resmed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amy Wakeham, VP Communications | ||
| Brett Sandercock, Chief Officer | ||
| BE MBA, CEO Director | ||
| Robert Douglas, Pres COO | ||
| Vered Keisar, Chief Officer | ||
| AM AM, Founder Chairman | ||
| David Pendarvis, Global Officer | ||
| Kaushik Ghoshal, Pres Bus | ||
| Constance Bienfait, Director Relations | ||
| Urvashi Tyagi, Chief Officer |
Resmed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Resmed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 31.38 B | |||
| Shares Outstanding | 1.47 B | |||
| Shares Owned By Institutions | 7.92 % | |||
| Price To Earning | 41.55 X | |||
| Price To Book | 9.35 X | |||
| Price To Sales | 8.00 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Resmed Stock
Resmed financial ratios help investors to determine whether Resmed Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Resmed with respect to the benefits of owning Resmed security.